Z83.41

Clinical Causes: Autosomal dominant inheritance pattern, meaning only one copy of the mutated gene from either parent can cause the disorder. Mutations in the RET proto-oncogene are primarily linked to MEN type 2 (MEN2). Mutations in the MEN1 gene are associated with MEN type 1 (MEN1). Family members carrying these mutations have a higher risk of developing tumors in multiple endocrine glands. Genetic testing can identify carriers of these mutations before symptoms appear.

Key Symptoms: Symptoms related to tumors in the parathyroid glands, such as hypercalcemia and kidney stones. Features of thyroid tumors, including a lump or swelling in the neck (medullary thyroid carcinoma). Pancreatic endocrine tumors that can cause symptoms like unexplained weight loss, abdominal pain, or hormonal syndromes (e.g., insulinoma causing hypoglycemia). Skin findings such as mucosal neuromas or sukker syndrome (specific to MEN2). Early onset of symptoms, often during adolescence or early adulthood in hereditary cases.

Diagnosis Path: Reviewing detailed family medical history for patterns of endocrine tumors. Genetic testing to identify mutations in the MEN1 and RET genes. Biochemical tests to detect hormonal imbalances caused by tumors in endocrine glands. Imaging studies such as ultrasound, MRI, or CT scans to locate tumors. Regular screening for at-risk individuals to monitor for early signs of tumor development.

Treatment Protocols: Surgical removal of tumors when detected early to mitigate complications. Medications to control hormone overproduction, such as calcium-lowering drugs for hyperparathyroidism. Targeted therapies for specific tumor types, including tyrosine kinase inhibitors for RET mutations in MEN2. Regular surveillance programs to detect new tumors early. Genetic counseling for affected families to understand inheritance risks and screening options. Preventive surgeries may be considered for high-risk individuals, especially in MEN2 cases with RET mutations.